Benzoyl peroxide/tretinoin - Bausch Health Companies
Alternative Names: IDP-120Latest Information Update: 17 Oct 2021
At a glance
- Originator Ortho Dermatologics
- Developer Bausch Health Companies; Ortho Dermatologics
- Class Anti-infectives; Antiacnes; Benzoic acids; Keratolytics; Oxidants; Peroxides; Retinoids; Skin disorder therapies; Small molecules
- Mechanism of Action Keratinocyte inhibitors; Myeloid-derived suppressor cell modulators; Protein synthesis inhibitors; Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Acne vulgaris
Most Recent Events
- 17 Oct 2021 Phase III development is ongoing in USA and Canada (Orth Dermatologics pipeline, October 2021)
- 20 Aug 2020 Bausch Health Companies completes the phase III trial in Acne vulgaris (In Children, In adolescent, In Adults, In Elderly) in USA and Canada (Topical) (NCT03664752)
- 23 Mar 2020 Bausch Health Companies completes a phase III clinical trial in Acne vulgaris (In adolescents, In children, In adults, In the elderly) in Canada and USA (Topical) (NCT03664739)